论文部分内容阅读
目的观察吉西他滨联合卡铂治疗Ⅲ期非小细胞肺癌的疗效和毒副作用。方法36例非小细胞肺癌患者,吉西他滨1200mg/m2d1、d8静点、卡铂AUC=5d1静点。21d～28d为1个周期。结果36例中PR19例,SD13例,PD4例,客观有效率(CR+PR)为53%,中位生存期14个月,1年生存率为61%,2年生存率为27%。毒副作用主要为骨髓抑制。结论吉西他滨联合卡铂治疗晚期非小细胞肺癌有效率高,提高了患者生存质量,毒副作用可耐受。
Objective To observe the efficacy and side effects of gemcitabine and carboplatin in the treatment of stage Ⅲ non-small cell lung cancer. Methods 36 patients with non-small cell lung cancer, gemcitabine 1200mg / m2d1, d8 static point, carboplatin AUC = 5d1 static point. 21d ~ 28d for a period. Results Among the 36 cases, there were 19 cases of PR, 13 cases of SD and 4 cases of PD. The objective effective rate (CR + PR) was 53%. The median survival time was 14 months. The 1-year survival rate was 61% and the 2-year survival rate was 27%. The main side effects of bone marrow suppression. Conclusion Gemcitabine combined with carboplatin in the treatment of advanced non-small cell lung cancer has high efficiency, improve the quality of life of patients, toxic side effects can be tolerated.